-

06:07:12 AM

NRSN Stock News

NRSN - NeuroSense Therapeutics Ltd

08/02/22 8:30 AM

Nasdaq : NRSN

low float

NeuroSense Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study

- NeuroSense's support will aid EverythingALS with ground-breaking patient research in a joint effort to develop treatments- NeuroSense's CEO to present at EverythingALS's Expert Talk Series on August 3, 2022; To listen to Mr. Ben-Noon's presentation register here: LINKLOS ALTOS, Calif. and

RHEA-AI

positive

07/28/22 9:00 AM

Nasdaq : NRSN

low float

NeuroSense Therapeutics and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers Using AI and ML

NeuraLight's platform technology uses computer vision, artificial intelligence (AI), deep learning algorithms, and machine learning (ML) to identify and track oculometric digital biomarkers to transform clinical development, diagnostics, and precision medicine in neurology The NeuroSense-NeuraLight

RHEA-AI

very positive

07/18/22 8:30 AM

Nasdaq : NRSN

low float

NeuroSense Therapeutics CEO Provides Key Corporate Update Video

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today released a corporate update video from its Founder and CEO Alon

RHEA-AI

neutral

07/12/22 5:00 AM

Nasdaq : CHMA, NRSN

management

SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer

SpyBiotech, a British biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Mark Leuchtenberger as its Chief Executive Officer. Mark Leuchtenberger recently served as Executive Chairman for Aleta Biotherapeutics and previously as...

RHEA-AI

neutral

06/30/22 8:30 AM

Nasdaq : NRSN

low float

NeuroSense Therapeutics Reports Positive Preliminary Results from Novel Alzheimer's Biomarker Study

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments

RHEA-AI

neutral

06/27/22 8:30 AM

Nasdaq : NRSN

low float

NeuroSense Therapeutics Reports Positive Results from Stage III ALS Biomarker Study

Preliminary results show levels of disease-related biomarkers remain unchanged in people living with ALS who are treated with standard of care, in contrast to the statistically significant decline in these biomarkers in patients treated in NeuroSense's Phase IIa study with PrimeC New biomarker data

RHEA-AI

neutral

06/22/22 8:30 AM

Nasdaq : NRSN

low float

NeuroSense CEO to be Panelist at Maxim Group's Innovations in ALS: Exploring New Treatments In Development on June 28, 2022

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the Company will participate in Maxim Group's panel discussion on Innovations in ALS: Exploring New

RHEA-AI

neutral

06/01/22 8:30 AM

Nasdaq : NRSN

low float

NeuroSense Enrolls First Patient in Phase IIb ALS Trial for its Combination Therapy PrimeC

RHEA-AI

very positive

05/31/22 8:30 AM

Nasdaq : NRSN

earningslow float

NeuroSense Announces First Quarter 2022 Financial Results and Provides Business Update

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today reported its financial results for the quarter ended March 31, 2022 and provided a business update.Business

RHEA-AI

neutral

05/23/22 8:30 AM

Nasdaq : NRSN

conferenceslow float

NeuroSense Therapeutics to Present at the ALS Drug Development Summit in Boston on May 26, 2022

RHEA-AI

very positive

NRSN Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.neurosense-tx.com
Security nameNeuroSense Therapeutics Ltd
Issue typecs
SectorManufacturing
Sic code2834

About NeuroSense Therapeutics Ltd

NeuroSense Therapeutics is a clinical-stage biopharmaceutical company, focusing on the discovery and development of targeted innovative therapeutics for neurodegenerative diseases. NeuroSense was founded in 2017 by Alon Ben-Noon, following a chance meeting with Shay Rishoni, an ALS patient. During this meeting, Alon was inspired by Shay, who served as the CEO of a non-profit organization for ALS. Despite Shay not having a physical voice, therefore communicating via eye movement and computer software, the connection was instant. Shay detailed his activities in the ALS field, and described the efforts that are being made to solve the ALS puzzle, leading Alon to team up with world-renowned scientists and colleagues in order to research and develop an effective drug for ALS patients, bringing about the establishment of NeuroSense. To date, the company has commenced with a breakthrough treatment for ALS that will halt, or significantly delay disease progression, as well as developments for Alzheimer’s and Parkinson’s diseases. NeuroSense is focused on creating a combined therapeutic strategy, targeting multiple pertinent mechanisms in these complex diseases. Its research team and advisory board members are multidisciplinary professionals who have many years of experience with drug development and clinical programs, as well as personal connections to neurodegenerative diseases. Their collective expertise and background enable us to move in a fast and efficient manner to achieve its goals. NeuroSense is currently preparing for a phase 2b/3 clinical trial using PrimeC in patients with ALS. NeuroSense is also commencing research into other possible indications for the drug, including Alzheimer’s and Parkinson’s diseases. Additionally, NeuroSense is studying the mechanisms of action and relevant biomarkers for these diseases.